相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
T. P. Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
Konstantin Byrgazov et al.
HAEMATOLOGICA (2018)
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
B. Peter et al.
LEUKEMIA (2018)
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
Konstantin Byrgazov et al.
HAEMATOLOGICA (2018)
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
Elena Arrigoni et al.
STEM CELLS TRANSLATIONAL MEDICINE (2018)
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
Georg E. Winter et al.
MOLECULAR CELL (2017)
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
Simon J. Hogg et al.
CELL REPORTS (2017)
Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia
G. Wedeh et al.
LEUKEMIA (2015)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert et al.
NATURE (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Matthew S. Zabriskie et al.
CANCER CELL (2014)
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
Jamshid S. Khorashad et al.
BLOOD (2013)
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling
Bin Zhang et al.
BLOOD (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
Georg E. Winter et al.
NATURE CHEMICAL BIOLOGY (2012)
The Histone Code and Treatments for Acute Myeloid Leukemia
Lucy A. Godley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting Epigenetic Readers in Cancer
Mark A. Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia (AML)
Harald Herrmann et al.
ONCOTARGET (2012)
Cancer stem cell definitions and terminology: the devil is in the details
Peter Valent et al.
NATURE REVIEWS CANCER (2012)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
Rajesh R. Nair et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
ERK2, but Not ERK1, Mediates Acquired and De novo Resistance to Imatinib Mesylate: Implication for CML Therapy
Clara I. Aceves-Luquero et al.
PLOS ONE (2009)
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
Elias Jabbour et al.
BLOOD (2008)
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease
Peter Valent
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia
Alfonso Quintas-Cardama et al.
CLINICAL CANCER RESEARCH (2008)
Chronic myeloid leukemia stem cells
Edward Kavalerchik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
L. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Right on target: eradicating leukemic stem cells
Daniela S. Krause et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation
Franck E. Nicolini et al.
HAEMATOLOGICA (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Ellen Weisberg et al.
NATURE REVIEWS CANCER (2007)
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
X. Jiang et al.
LEUKEMIA (2007)
Primitive, quiescent and difficult to kill - The role of non-proliferating stem cells in chronic myeloid leukemia
David J. Barnes et al.
CELL CYCLE (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation
JV Melo et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Critical role for Gab2 in transformation by BCR/ABL
M Sattler et al.
CANCER CELL (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The molecular biology of chronic myeloid leukemia
MWN Deininger et al.
BLOOD (2000)
分享论文
